Gilead Sciences Inc. (NASDAQ:BROWN) is one of the best stocks for the next decade. On Dec. 12, Morgan Stanley raised the company’s price target for Gilead to $151 from $147 with an Overweight rating on the stock. The company informed investors that the regulatory and political uncertainties currently weighing on the biopharmaceutical are expected to decrease. As these political issues dissipate, Morgan Stanley anticipates a shift in market attention toward the industry’s core financial and operational performance.
Subsequently, on December 15, Gilead Sciences Inc. (NASDAQ:GILD) announced positive results from its Phase 3 ARTISTRY-2 clinical trial. The study demonstrated that an investigational single-tablet regimen combining bictegravir (75 mg) and lenacapavir (50 mg), called BIC/LEN, is not statistically inferior to the current standard of care, BIKTARVY. This trial focused on adults with virologically suppressed HIV-1 who switched from BIKTARVY to the new combination, meeting the primary efficacy endpoint of maintaining HIV-1 RNA levels below 50 copies/ml at week 48.
Gilead plans to use the ARTISTRY-2 results along with data from the ARTISTRY-1 trial, which announced similar non-inferiority results in November, as a basis for upcoming regulatory filings. The company intends to present detailed results at a future scientific conference. These advancements represent a significant step in Gilead’s 35-year history of HIV innovation, potentially offering a new, simplified treatment option for the millions of people living with the virus around the world.
Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need in the US, Europe and internationally.
While we recognize GILD’s potential as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 30 stocks that should double in 3 years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published in Internal jumpsuit.